The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global prostate cancer treatment market size reached US$ 6.81 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 10.09 Billion by 2027, exhibiting a growth rate (CAGR) of 6.32% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Prostate cancer is a type of severe malignant tumor, which is caused by the uncontrollable division and expansion of various abnormal cells in the prostate gland present in men. It can be treated through the use of various therapeutics, such as vaccines, medications, and treatments. Amongst these, chemotherapy, immunotherapy, cryotherapy, surgery, hormonal, targeted and radiation therapy are some of the most common treatment types that aid in mitigating the spread of cancer cells in the body. These therapies are provided to the patient based on various assessments, such as the age of the patient, severity of the symptoms experienced, medical condition, and previous health history.
The increasing prevalence of prostate cancer, especially amongst the rising geriatric population, is one of the prime factors currently driving the market toward growth. In line with this, the availability of favorable medical reimbursement policies and the numerous initiatives being undertaken by the government bodies of several countries for introducing patient assistance programs (PAPs) are acting as other growth-inducing factors. PAP is an organized program, which is controlled by pharmaceutical companies for providing financial assistance to patients by offering free medications for treatment purposes. Moreover, significant technological advancements, such as the integration of multiparametric-magnetic resonance imaging (mp-MRI) devices with non-metastatic castration-resistant (nmCRPC) and metastatic hormone nave (mHNPC) settings for detecting prostate cancer at early stages, while mitigating diagnostic errors, is also contributing to the market growth. Additionally, extensive investments in the research and development (R&D) activities to introduce novel therapeutic products, along with their easy availability across various online and offline distribution channels, are creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global prostate cancer treatment market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on drug type and distribution channel.
Breakup by Drug Type:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Astellas Pharma Inc., AstraZeneca plc, Bayer Aktiengesellschaft, Dendreon Pharmaceuticals LLC. (Sanpower Group Co. Ltd.), F. Hoffmann-La Roche AG, Ferring B.V., GlaxoSmithKline Plc, Ipsen (Mayroy SA), Novartis International AG, Takeda Pharmaceutical Company Ltd. and Tolmar Pharmaceuticals Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Drug Type, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Astellas Pharma Inc., AstraZeneca plc, Bayer Aktiengesellschaft, Dendreon Pharmaceuticals LLC. (Sanpower Group Co. Ltd.), F. Hoffmann-La Roche AG, Ferring B.V., GlaxoSmithKline Plc, Ipsen (Mayroy SA), Novartis International AG, Takeda Pharmaceutical Company Ltd. and Tolmar Pharmaceuticals Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at